Navigation Links
Stematix™ Obtains Exclusive License to Regenexx™ Stem Cell Procedure Treating Musculoskeletal Diseases in Latin America
Date:10/24/2009

License Strengthens Stematix's Regenerative Treatments

Houston, TX (PRWEB) October 23, 2009 -- Stematix Inc., announced today it has signed an exclusive royalty-bearing license agreement, for the Latin American territory, to use an innovative process that rapidly grows a patients own adult stem cells to treat a variety of musculoskeletal diseases.

Stematix which is establishing international therapy clinics in public-private partnerships to provide near-term and approved stem cell treatments for hundreds of millions of patients that could potentially benefit.

Through its and its partners' industry know-how and experience, Stematix has developed a suite of commercial products and solutions to help the stem cell research community and also global partners establish world-class stem cell therapy, banks and therapy clinics in a cost-effective and timely manner.

The licensed procedure has been developed by Regenerative Sciences, LLC, a Colorado-based company focused on developing a medical procedure for the treatment of chronic orthopedic conditions. Known under the name Regenexx™, the innovative outpatient procedure takes stem cells from an individual's bone marrow, isolates mesenchymal stem cells (which can grow into bone, tendon, muscle, ligament and cartilage), cultures them in a solution containing unique elements from the individual's own blood, and generates millions of stem cells over two to three weeks. These cells are then re-injected into the person's joints or bones in an office procedure to assist in tissue healing and restoration of bone and cartilage. The Regenexx Procedure has helped many patients avoid more risky and costly surgical intervention.

Additionally, Regenerative Sciences' founder and CEO, Christopher Centeno, M.D., has agreed to serve as a consultant to Stematix Inc. in the area of stem cell therapy in orthopedics. Dr. Centeno is an international expert in musculoskeletal, spinal and neurological injury. Dr. Centeno will continue to assist Stematix in using mesenchymal stem cell isolation and transplantation methods abroad in the lab and clinical setting. He will also train personnel in Colorado in mesenchymal stem cell isolation, preparation and transplantation methods.

David C. Bonner, Ph.D., Chairman and CEO of Stematix, said, "We at Stematix are excited to be working with Regenexx, the leaders in applied regenerative medicine for orthopedics. We anticipate that this cutting edge, proven treatment will provide needed care for many patients in clinics established in Latin America. We are working toward a first clinic in Argentina during 2010. The expertise and experience of Dr. Centeno and Dr. Schulz will be invaluable in establishing our clinic in Argentina, and we look forward to incorporating advances in the treatment methodology that the Regenexx clinic in Denver will lead. "

Dr. Centeno said, "I look forward to working with Stematix and their team to bring Regenerative Science's important stem cell innovations to a worldwide audience of doctors and patients. I'm especially excited about Stematix's relationships and its expanding presence in Latin America."

About Stematix™, Inc.
Stematix is a regenerative medicine therapy company poised to accelerate safe and effective use of stem cell therapies globally. Stematix is establishing international therapy clinics in public-private partnerships that provide near-term and approved stem cell treatments for hundreds of millions of patients that could potential benefit. Through industry partnerships, Stematix has developed a suite of commercial products and solutions to help the stem cell research community and also global partners establish word-class stem cell therapy, banks and therapy clinics in a cost-effective and timely manner.

For more information, please visit: Regenexx .

Contact:   
Stematix.
Ms. Timmie Wang, Vice President Business Development
T: +1-713-212-0671

Regenerative Sciences.
Carl R. Measer, MBA, Chief Operating Officer
T: 303-429-6448
www.regenexx.com

# # #

Read the full story at http://www.prweb.com/releases/2009/10/prweb3090364.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Karmanos Cancer Institute Immunology Researcher Obtains Nearly $1 Million National Institutes of Health Grant
2. Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government
3. Simcere Pharmaceutical Group Invested Company Obtains Production License for H1N1 Flu Vaccine
4. Occlutech and IZASA Obtains Favourable Ruling in Proceeding Initiated by AGA Medical in Spain
5. Imagenetix (IAGX) Obtains Apology
6. Nfocus Neuromedical Obtains CE Approval for New Vascular Reconstruction Device
7. China Sky One Medical, Inc. Obtains Renewal of GMP Certificate
8. RainEarth Obtains Patent Approvals for Its Core Technology
9. China Sky One Medical, Inc. Obtains Production License Renewal for Sumei Slim Patch
10. China Sky One Medical, Inc. Obtains SFDA Approval for Diclofenac Sodium Eye Drops
11. Occlutech Obtains CE Mark for the new Generation PFO & ASD Occluders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: